A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 440
Last updated 2026-05-13
Summary
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
- DRUG
-
BMS-986393
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
-
Celgene Corporation
collaborator INDUSTRY -
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-12
- Primary Completion
- 2027-12-30
- Completion
- 2032-06-22
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Czechia
- Denmark
- Finland
- France
- Germany
- Greece
- Hungary
- Israel
- Italy
- Japan
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Saudi Arabia
- Singapore
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03859427 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06232707 ·Status: WITHDRAWN ·Phase: PHASE3
-
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01239797 ·Status: COMPLETED ·Phase: PHASE3
-
Limited-duration Teclistamab
NCT05932680 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
NCT01549431 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
NCT00721734 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03651128 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
NCT06232096 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498 ·Status: RECRUITING ·Phase: PHASE3
-
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383 ·Status: RECRUITING ·Phase: PHASE2
-
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078 ·Status: COMPLETED ·Phase: PHASE2
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06126237 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines
NCT03155100 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT04855136 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00065351 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150 ·Status: RECRUITING ·Phase: PHASE3
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06163898 ·Status: TERMINATED ·Phase: PHASE1
-
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT04150965 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
NCT00742560 ·Status: COMPLETED ·Phase: PHASE2